(MYGN) Myriad Genetics, Inc. Porters Five Forces Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(MYGN) Myriad Genetics, Inc. Complete Analysis Pack
From Overview to Strategy Blueprint
This Myriad Genetics, Inc. Porter's Five Forces Analysis helps you quickly assess the company’s competitive environment, including rivalry, supplier power, buyer power, substitutes, and new entrants. The page already shows a real preview of the report, so you can review the actual content before buying. Purchase the full version for the complete ready-to-use analysis.
Suppliers Bargaining Power
Specialized assay inputs
Myriad Genetics, Inc. depends on specialized reagents, sequencing platforms, and bioinformatics tools to run its genetic tests, so suppliers of these inputs can matter a lot. Because many inputs are highly specific and hard to swap, Myriad has limited room to change vendors without risking test quality or turnaround time. That gives key suppliers leverage on pricing and supply terms, especially for assay-critical materials.
Platform dependence
In 2025, Myriad Genetics, Inc. still depended on third-party instrumentation and lab technologies to run its testing workflow. That gives key platform partners real leverage: any change in pricing, access, or support can lift costs or slow new test launches. Supplier power is moderate, not extreme, because Myriad can switch some inputs, but not without time and expense.
Data and software vendors
Myriad Genetics, Inc. depends on secure cloud, lab, and informatics tools to interpret genomic data, and these systems are not easy to swap fast. In 2025, that means vendors handling compliance, analytics, and data storage can still hold some leverage, because a lab workflow pause can hit test turnaround and revenue. Supplier power is only moderate, but it rises when replacement takes months, not days.
Limited but qualified providers
Supplier power is moderate to high because Myriad Genetics relies on clinical-grade reagents, instruments, and certified lab inputs that must pass CLIA, CAP, and FDA-aligned quality checks. That narrows the supplier pool versus normal healthcare buying, so qualified vendors can demand better terms, and switching can disrupt test accuracy and turnaround time.
- Fewer approved suppliers
- Strict accuracy standards
- Higher switching risk
- More vendor leverage
Partnership leverage
Myriad Genetics’ supplier power is moderate because alliances can widen access to technology and distribution, especially with partners like Illumina. The tradeoff is dependence on outside innovation and commercialization terms, which can squeeze margins and limit flexibility if partner economics shift.
- Partnerships expand reach and tech access.
- They also raise dependence risk.
- Supplier power stays moderate overall.
Myriad Genetics Faces Moderate Supplier Power in 2025
Supplier power is moderate for Myriad Genetics, Inc. because it depends on approved reagents, instruments, and cloud/informatics vendors, but it can still switch some inputs over time. The risk is highest where CLIA/CAP-grade lab materials and data systems are hard to replace without hurting test quality or turnaround.
| 2025 factor | Effect |
|---|---|
| Qualified lab inputs | Higher supplier leverage |
| Partner tech and software | Moderate lock-in |
| Switching costs | Raise vendor power |
What is included in the product
Detailed Word Document
Tailored to Myriad Genetics, Inc., this analysis maps competitive pressures, supplier and buyer power, entry threats, and substitutes shaping profitability.
Customizable Excel Spreadsheet
A clear, one-page view of Myriad Genetics’ five forces—so you can spot risks and opportunities fast.
Reference Sources
Provides a clear reference trail for Myriad Genetics data, strengthening credibility and speeding confident decisions.
Customers Bargaining Power
Payor reimbursement pressure
Health insurers and public payors set the terms for Myriad Genetics, Inc.’s test uptake, so reimbursement pressure keeps customer power high. When coverage narrows or payment rates fall, test volume and gross margin can drop fast; in 2025, this risk stayed central for molecular diagnostics as payors kept tightening prior-authorization and medical-necessity rules.
Physician and hospital choice
Physician and hospital choice is a real pressure point for Myriad Genetics, Inc. Clinicians can pick from multiple genetic testing options on price, evidence, and workflow, while hospitals and labs often run vendor reviews before switching. That makes buyers harder to keep and pushes Myriad to defend pricing, service, and turnaround times.
Patient sensitivity to cost
Myriad Genetics, Inc. faces high buyer leverage because many of its tests are discretionary and can carry out-of-pocket costs. When clinical differences are small, patients and providers can shift to lower-cost options, which puts pressure on pricing and mix. Cost sensitivity is still high in U.S. care, with 1 in 4 adults skipping or delaying care because of cost.
High evidence requirements
Myriad Genetics faces high customer power because buyers want proof of clinical utility, fast turnaround, and easy EHR ordering. In FY2024, revenue was about $830 million, so losing even a small share matters. If Myriad cannot keep showing clear value, labs, payers, and health systems can shift volume to rivals, keeping switching pressure high.
Proof of value drives buying
Speed and integration matter
Switching risk stays elevated
That pressure is strongest in tests with close substitutes, where evidence and workflow fit often decide the win.
Concentrated institutional buyers
Large health systems and insurer networks buy Myriad Genetics, Inc. tests in bulk, so they can press for lower prices and tighter coverage rules. UnitedHealth Group served about 51 million U.S. medical members in 2025, while CVS Health covered about 26 million, showing how a few buyers can control access at scale. Buyer power is significant.
- Big networks negotiate harder.
- Coverage rules shape test volume.
- Patient switching power is low.
Myriad Faces Strong Buyer Power From Giant Payors
Customer power is high for Myriad Genetics, Inc. because payors, health systems, and clinicians can shift volume to rival genetic tests when coverage, price, or workflow is better. In 2025, large buyers like UnitedHealth Group served about 51 million U.S. medical members and CVS Health about 26 million, so a few networks can move demand fast.
| Driver | 2025 data |
|---|---|
| UnitedHealth medical members | 51 million |
| CVS Health covered lives | 26 million |
| Myriad revenue | about $830 million |
That scale keeps bargaining pressure high on price, coverage, and turnaround time.
Preview the Actual Deliverable
Myriad Genetics, Inc. Porter's Five Forces Analysis
This preview shows the exact Myriad Genetics, Inc. Porter's Five Forces Analysis you'll receive immediately after purchase—no surprises, no placeholders. The document displayed here is the same professionally written, ready-to-use file that will be available for instant download after payment. What you see is what you get, fully formatted and ready for your needs.
Rivalry Among Competitors
Crowded molecular diagnostics market
Myriad Genetics faces intense rivalry because dozens of national and regional labs sell overlapping tests in oncology, reproductive health, and mental health. In FY2025, that pressure stayed high as payers kept pushing prices down and clinicians could switch to larger platforms from Labcorp, Quest Diagnostics, Natera, and Exact Sciences. In a market this crowded, even small gains in reimbursement, turnaround time, or test accuracy can shift share fast.
Constant product innovation
Constant product innovation keeps rivalry high: competitors keep rolling out broader sequencing panels and faster turnaround tests, so Myriad Genetics, Inc. has to keep spending on R&D and launches to defend share. In a market where test menus can change in months, even a short lag can erode franchise value. That pressure is stronger in hereditary cancer and prenatal testing, where better panel depth and speed often win orders.
Price and reimbursement competition
Price and reimbursement competition is intense for Myriad Genetics, Inc. because payer coverage can swing demand fast: a single policy change can move test volumes from covered to denied. Genetic tests often carry list prices in the low-thousands of dollars, so small differences in contracted rates and Medicare or commercial reimbursement can change margins and market share quickly.
Overlap with major diagnostics firms
Myriad Genetics, Inc. competes with scaled diagnostics leaders like Labcorp, Quest Diagnostics, and specialized genomic firms such as Natera. Labcorp posted about $13.0 billion in 2024 revenue and Quest about $9.9 billion, giving them deeper sales reach and payer leverage than Myriad. That scale, plus strong brands and broad distribution, keeps pressure high in Myriad’s core oncology and hereditary testing markets.
- Big rivals have bigger sales forces.
- Brand trust cuts win rates.
- Distribution scale lowers unit costs.
Clinical evidence as battleground
Clinical evidence is the key battleground in Myriad Genetics, Inc.'s market. Winning shares depends on guideline inclusion, published data, and physician trust, so rivals pour money into trials and payer access to win endorsements. That keeps rivalry high and durable, especially in tests where clinical utility drives reimbursement.
- Guidelines shape ordering decisions.
- Evidence wins payer coverage.
- Trust drives repeat use.
Myriad Faces Fierce Rivalry From Labcorp and Quest
Competitive rivalry is high for Myriad Genetics, Inc. because it fights larger labs and niche genetic-testing peers on price, coverage, and evidence. FY2025 pressure stayed strong as payers squeezed rates and rivals like Labcorp and Quest Diagnostics kept scale advantages. Labcorp logged about $13.0 billion in 2024 revenue and Quest about $9.9 billion, so Myriad must win on test utility, speed, and reimbursement.
| Rival | Scale |
|---|---|
| Labcorp | 13.0B 2024 revenue |
| Quest Diagnostics | 9.9B 2024 revenue |
Substitutes Threaten
Standard clinical pathways
Standard clinical pathways can replace some Myriad Genetics tests when pathology, imaging, or symptoms already give a clear answer. In breast cancer, for example, most U.S. cases are first picked up through imaging and biopsy, so a test with uncertain added benefit faces real substitution pressure. That keeps the threat of substitutes meaningful, especially when payers want lower-cost care.
Alternative biomarker tests
Alternative biomarker tests can answer the same clinical questions through different assays, so Myriad Genetics, Inc. faces moderate substitution pressure. When other platforms are cheaper or easier to access, clinicians and payers may switch, especially in a U.S. diagnostics market with thousands of labs and broad test-menu competition. That said, Myriad Genetics, Inc.'s branded tests and evidence base help limit switching in higher-stakes cases.
Broader panel providers
Broader panel providers raise Myriad Genetics, Inc.'s substitution risk because labs can bundle many genes into one test instead of selling separate branded assays. Myriad Genetics, Inc.'s myRisk covers 48 genes, but rivals offer similar multi-gene panels, so buyers can switch on price, coverage, or convenience. That makes one broad panel a practical substitute for several single-purpose tests.
Therapy-guided clinical judgment
Therapy-guided clinical judgment is a real substitute: when a case is straightforward, physicians may skip a genomic test and act on history, imaging, and guidelines instead. That weakens demand for some Myriad Genetics, Inc. tests and makes the offer less unique when the expected treatment path is already clear.
- Lower test need in clear-cut cases
- Physician judgment can replace results
- Limits pricing power and volume
Emerging AI and non-genetic tools
Emerging AI and non-genetic risk models are a moderate, rising substitute threat for Myriad Genetics, Inc., especially in low- to mid-complexity triage. The FDA has cleared 1,000+ AI/ML medical devices, and if these tools gain clinical validation plus reimbursement, they can replace some test orders in select use cases.
- Validated AI can cut test demand.
- Reimbursement decides adoption speed.
- Highest risk: screening and triage.
Myriad Genetics Faces Rising Substitute Pressure
Threat of substitutes for Myriad Genetics, Inc. is moderate to high because clear-cut pathology, imaging, and physician judgment can replace some test orders. Broad panel rivals also mimic its use cases, and myRisk covers 48 genes, so buyers can switch on price, coverage, or convenience. AI and non-genetic risk tools add a rising substitute risk, especially in screening and triage.
| Substitute | Impact |
|---|---|
| Clinical judgment | Can skip testing |
| Broad gene panels | 48-gene competition |
| AI tools | 1,000+ FDA clearances |
Entrants Threaten
Heavy regulatory burden
Genetic testing has a heavy regulatory burden: entrants need CLIA lab certification, often CAP quality systems, HIPAA privacy controls, and, for some tests, FDA review. Building that compliance stack can take years and significant capital before any scale. That makes new entry slow, costly, and a major barrier for Myriad Genetics, Inc.
High clinical validation costs
A single multi-site clinical validation program can cost $1 million to $5 million or more, and payer coverage work adds more time and cash burn. For Myriad Genetics, that burden matters because new tests must prove utility across large patient sets before doctors and insurers adopt them. So startups can bring good science, but the cost of evidence and reimbursement support keeps the bar high and slows entry.
Brand and physician trust
Myriad Genetics has built brand trust over 30+ years in hereditary cancer and precision medicine, so new entrants must prove clinical value fast. Clinicians and payors already know Myriad’s tests, data, and workflows, which raises switching costs. That trust is a real barrier: a new lab must win reimbursement, referrals, and confidence at the same time.
Data and IP barriers
In FY2025, Myriad Genetics' edge came from proprietary datasets, variant-calling algorithms, and interpretation rules built over years of test use. Those assets are hard to copy because clinical learning improves with every result, so rivals cannot match the same accuracy fast. That makes entry costly and slows new entrants.
- FY2025 data moat is hard to copy.
- Large clinical databases widen the gap.
- Speed to match is the real barrier.
Capital and scale requirements
Capital and scale needs keep entry barriers high for Myriad Genetics, Inc. A new rival must fund lab buildout, CLIA/CAP quality systems, a national sales team, and payer contracting before it can win volume.
It also needs enough test scale to match Myriad Genetics, Inc. on cost and turnaround time. That makes the threat of new entrants moderate to low.
- High upfront lab spending
- Broad reimbursement work
- Scale drives lower unit cost
- Fast turnaround needs volume
Myriad Genetics Faces Low-to-Moderate New Entrant Threat
Threat of new entrants for Myriad Genetics, Inc. stays low to moderate because CLIA/CAP setup, payer work, and clinical validation are expensive and slow. In FY2025, Myriad Genetics' long-built data, algorithms, and brand trust made it hard for new labs to match accuracy, reimbursement, and turnaround at scale. New rivals can enter, but matching Myriad Genetics, Inc. on evidence and volume is the real barrier.
| Barrier | Why it matters |
|---|---|
| Lab buildout | High upfront capex |
| Validation | Long, costly studies |
| Reimbursement | Slow payer adoption |
| Data moat | Hard to copy in FY2025 |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.